NCT00797303

Brief Summary

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jan 2006

Typical duration for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2008

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2008

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

November 22, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 25, 2008

Completed
Last Updated

December 2, 2011

Status Verified

November 1, 2011

Enrollment Period

2.5 years

First QC Date

November 22, 2008

Last Update Submit

December 1, 2011

Conditions

Corneal Neovascularization

Keywords

bevacizumabcorneaneovascularization

Outcome Measures

Primary Outcomes (1)

  • The Effect of Bevacizumab on Corneal Neovascularization

    Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography

    Compare the results

Study Arms (1)

1

EXPERIMENTAL

A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up

Drug: Bevacizumab

Interventions

BevacizumabDRUG

subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

1

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Corneal Neovascularization
  • Stable lesion

You may not qualify if:

  • Diabetes
  • Autoimmune diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Corneal NeovascularizationCorneal DiseasesNeovascularization, Pathologic

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Eye DiseasesMetaplasiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Officials

  • Belquiz A Nassaralla, PhD

    Instituto de Olhos de Goiânia

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

November 22, 2008

First Posted

November 25, 2008

Study Start

January 1, 2006

Primary Completion

July 1, 2008

Study Completion

November 1, 2008

Last Updated

December 2, 2011

Record last verified: 2011-11